Comparison of Sutureless Aortic Valve Replacement and Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis of Propensity Score Matching

Shidong Liu, Hao Chen, Wenjun Zhou, Pengying Zhao, Liang Qi, Yalan Zhang, Bing Song, Cuntao Yu · 2024

Read Comparison of Sutureless Aortic Valve Replacement and Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis of Propensity Score Matching by Shidong Liu, Hao Chen, Wenjun Zhou, Pengying Zhao, Liang Qi, Yalan Zhang, Bing Song, Cuntao Yu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11607518.txt.

Introduction

Shidong Liu and co-authors pool matched studies to compare two ways of replacing a heart valve, in a 2024 review. One way is open surgery with a valve that needs no stitches. The other threads a new valve in through a vessel. Both treat a narrowed aortic valve, a common problem in older adults.

The review gathered 16 studies that matched patients by risk profile. In all, 6,516 patients were split evenly between the two methods. The surgery group had lower death rates at one, two, and five years. Other outcomes, such as leaks and pacemaker needs, were also pooled. Matched pooling cannot equal a trial, but it gives a broad view of how the two routes compare.

Catalog record

CREATORShidong Liu, Hao Chen, Wenjun Zhou, Pengying Zhao, Liang Qi, Yalan Zhang, Bing Song, Cuntao Yu
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11607518

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Comparison of Sutureless Aortic Valve Replacement and Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis of Propensity Score Matching Authors: Shidong Liu, Hao Chen, Wenjun Zhou, Pengying Zhao, Liang Qi, Yalan Zhang, Bing Song, Cuntao Yu Published: 2024 ABSTRACT Background:To evaluate the clinical outcomes of sutureless aortic valve replacement (SUAVR) and transcatheter aortic valve implantation (TAVI).Methods:We systematically searched the electronic database and the Clinical Trials Registry up to 31 February 2023. Random effects model risk ratio (RR) and mean differences (MD) with corresponding 95% confidence intervals (CIs) were pooled for the clinical outcomes. Results:The included 16 studies using propensity-matched analysis consisted of 6516 patients, including 3258 patients in the SUAVR group and 3258 patients in the TAVI group. The SUAVR group had lower mortality than the TAVI group at 1-year [RR = 0.53, 95% CI (0.32, 0.87), I2 = 49%, p = 0.01], 2-year [RR = 0.56, 95% CI (0.37, 0.82), I2 = 51%, p = 0.03] and 5-year [RR = 0.56, 95% CI (0.46, 0.70), I2 = 0%, p < 0.01]. The SUAVR group had a significantly lower rate of new permanent pacemaker implantation (PPI) [RR = 0.74, 95% CI (0.55, 0.99), I2 = 48%, p = 0.04], moderate-to-severe paravalvular leak (PVL) [RR = 0.18, 95% CI (0.11, 0.30), I2 = 0%, p < 0.01], more-than-mild residual aortic regurgitation (AR) [RR = 0.27, 95% CI (0.14, 0.54), I2 = 0%, p < 0.01]. In addition, the SUAVR group had a higher rate of new-onset atrial fibrillation (AF) [RR = 3.66, 95% CI (1.95, 6.89), I2 = 84%, p < 0.01], major or life-threatening bleeding event [RR = 3.63, 95% CI (1.81, 7.28), I2 = 83%, p < 0.01], and higher postoperative mean aortic gradient [MD = 1.91, 95% CI (0.73, 3.10), I2 = 91%, p < 0.01] than the TAVI group. Conclusions:The early and mid-term clinical outcomes of SUAVR were superior compared to TAVI. Further studies should be conducted to highlight the specific subgroups of patients. that will benefit from each technique.INPLASY Registration Number:INPLASY 2022110058 (https://inplasy.com/inplasy-2022-11-0058/). 1. Introduction In the treatment of patients with aortic valve stenosis (AS), the prognoses of surgical aortic valve replacement (SAVR) are reproducible and well established [1]. However, transcatheter aortic valve implantation (TAVI) has been introduced into surgical practice as new alternative treatment in the last ten years, which has shown favorable clinical and hemodynamic results in AS patients at intermediate or high surgical risk [2, 3], and which is expanding to low-risk patients [4, 5]. The lack of removal of the diseased and calcified aortic valve tissue, resulting in an increased risk of post-operative complications, has been acknowledged as a major limitation of TAVI [6, 7, 8]. With the development of stentless valves, sutureless aortic valve replacement (SUAVR) has been proposed as another treatment option for AS patients to overcome these limitations of TAVI [9]. Sutureless valves are made of biological tissue and can be quickly implanted, which reduces aortic cross-clamp and cardiopulmonary bypass time compared to conventional sutured valves [10, 11], and facilitates the use of a newer less invasive surgical techniques [12]. Thus, SUAVR is expected to reduce postoperative complications and improve the quality of life for AS patients. SUAVR may potentially have a patient cohort similar to TAVI, therefore the objective of this systematic review and meta-analysis was to evaluate the clinical outcomes of SUAVR and TAVI. 2. Methods 2.1 Date Source and Search Strategy We systematically searched electronic databases (PubMed, Cochrane library, EMbase and MEDLINE) and the Clinical Trials Registry (https://www.clinicaltrials.gov) until February 31, 2023. The search strategy used the combination of “Surgical Procedure, Sutureless”, “Sutureless technique”, “Sutureless Surgical Procedures” and “Transcatheter Aortic Valve Implantation”, “Transcatheter Aortic Valve Replacement”, “TAVI”, “TAVR” with no restrictions on language. References from the reviewed studies were also screened to identify additional articles. 2.2 Eligibility Criteria Studies were included if they met the following criteria, based on patient, intervention, comparison, endpoint, and study design: (1) the patient underwent SUAVR or TAVI with no restrictions on surgical risk, (2) the intervention was SUAVR regardless of the valve type, (3) the comparison group was TAVI regardless of the valve style, (4) primary endpoint: mortality at various follow-up periods. Secondary outcomes: moderate-to-severe paravalvular leak (PVL), more-than-mild residual aortic regurgitation (AR), myocardial infarction (MI), major vascular complication, new permanent pacemaker implantation (PPI), stroke, new renal replacement therapy, new-onset atrial fibrillation (AF), major or life-threatening bleeding event, postoperative mean aortic gradient, intensive care unit (ICU) length of stay, cross-clamp time and cardiopulmonary bypass (CPB) time. Primary endpoints were defined based on the Valve Academic Research Consortium-2 definitions and major or life-threatening bleeding event were defined based on the Bleeding Academic Research Consortium (BARC), (5) comparative studies with propensity-matched analysis. 2.3 Study Selection and Data Extraction Two authors (PZ and WZ) independently screened studies using the following criteria: (1) removal of duplicates; (2) selection of titles and abstracts based on inclusion/exclusion criteria; (3) evaluation of eligibility by reading the full text; (4) determination of included studies. Disagreements were resolved by discussions with a third reviewer (SL) or by consensus. This study was a systematic review and meta-analysis, and therefore ethical and patient approval was not required. The study data were extracted by two authors (LQ and YZ) independently and included: first author, publication year, study design, number of patients, patient demographics, medical history, procedural characteristics, outcomes and follow-up time. Data were then revised by a third reviewer (HC) for accuracy. Discrepancies regarding data incorporation were resolved by consensus among all authors. 2.4 Quality Assessment and Statistical Analysis The quality of the included studies were evaluated by the Newcastle-Ottawa Scale (NOS) [13] including: (1) patient selection, (2) comparability of the study groups, and (3) the assessment of outcomes. Categorical variables were denoted by numbers and percentages, and continuous variables were reported as standardized mean and standard deviation. The pooled results of dichotomous endpoints were estimated by risk ratio (RR) and 95% confidence intervals (CIs) with the Mantel-Haenszel method. The pooled data of continuous endpoints were assessed by mean differences (MD) with 95% CIs with the inverse-variance method. Heterogeneity assessments were performed using χ2-based Q statistics and I2 tests. A p < 0.10 or I2 > 50% were considered as significant heterogeneity. The RRs and MDs were combined using the random effect model. As a sensitivity analysis, by excluding one study in each turn, we analyzed the results in the presence of heterogeneity to assess the robustness and potential effect modifiers. The publication bias was evaluated visually using funnel plots, and Peter’s or Egger’s test [14, 15] was used to quantify publication bias. p < 0.05 was considered statistically significance in this meta-analysis. All pooled analyses were calculated using the R version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria). 3. Results 3.1 Study Characteristics and Quality Assessment 308 studies were included in the preliminary search, of which 27 studies were potentially relevant and the full text was read. Finally, a total of 16 studies were included [16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31] (Fig. 1). After propensity-matched analysis, 3258 SUAVR and 3258 TAVI patients were included in each group for a total of 6516 patients. The patient demographics and quality assessment

Read the complete text